Compensatory growth factor and cytokine response in tears after subconjunctival bevacizumab injection

Cornea

Volumn 30, Issue 10, 2011, Pages 1071-1077

  Jeong, Jae Hoon ^a   Chun, Yeoun Suk ^a   Kim, Eung Suk ^a   Kim, Jae Chan ^a  

^a Chung Ang University College of Medicine   (South Korea)

Author keywords

bevacizumab; corneal neovascularization; cytokine; growth factor; tear

Indexed keywords

BEVACIZUMAB; CYTOKINE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GELATINASE B; GROWTH FACTOR; INTERLEUKIN 1BETA; LEVOFLOXACIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CORNEA DISEASE; CORNEA NEOVASCULARIZATION; DRUG EFFECT; DRUG SAFETY; EYE PHOTOGRAPHY; FEMALE; HUMAN; IMMUNE RESPONSE; LACRIMAL FLUID; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PUNCTATE EPITHELIAL EROSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CORNEAL NEOVASCULARIZATION; CYTOKINES; EYE PROTEINS; FEMALE; HUMANS; IMMUNOASSAY; INJECTIONS, INTRAOCULAR; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; TEARS;

EID: 80052782941     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31820cd3f4     Document Type: Article

References (33)

1. Folkman J, Ingber D. Inhibition of angiogenesis. Semin Cancer Biol. 1992;3:89-96.
2. Battegay EJ. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med. 1995;73:333-346.
3. Zhang SX, Ma J-X. Ocular neovascularization: implication of endogenous angiogenic inhibitors and potential therapy. Prog Retin Eye Res. 2007;26: 1-37. (Pubitemid 44920203)
4. Loughman MS, Chatzistefanou K, Gonzalez EM, et al. Experimental corneal neovascularisation using sucralfate and basic fibroblast growth factor. Aust N Z J Ophthalmol. 1996;24:289-295. (Pubitemid 26405309)
5. Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/ vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146:1029-1039.
6. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983-985.
7. Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2007;245:68-73. (Pubitemid 46766732)
8. Jorge R, Costa RA, Calucci D, et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina. 2006;26:1006-1013. (Pubitemid 44973219)
9. Iliev ME, Domig D, Wolf-Schnurrbursch U, et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol. 2006;142:1054-1056. (Pubitemid 44853889)
10. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res. 2008;33:23-28. (Pubitemid 351156952)
11. Uy HS, Chan PS, Ang RE. Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson syndrome. Cornea. 2008;27:70-73.
12. Awadein A. Subconjunctival bevacizumab for vascularized rejected corneal grafts. J Cataract Refract Surg. 2007;33:1991-1993. (Pubitemid 47615364)
13. Carrasco MA. Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis. Cornea. 2008;27:743-745.
14. Sawada O, Kawamura H, Kakinoki M, et al. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol. 2007; 125:1363-1366. (Pubitemid 47606601)
15. Chan WM, Lai TY, Chan KP, et al. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia. Retina. 2008;28:1308-1313.
16. Zhu Q, Ziemssen F, Henke-Fahle S, et al. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology. 2008;115:1750-1755.
17. Hanneken A, de Juan E Jr, Lutty GA, et al. Altered distribution of basic fibroblast growth factor in diabetic retinopathy. Arch Ophthalmol. 1991; 109:1005-1011.
18. Patel B, Hiscott P, Charteris D, et al. Retinal and preretinal localisation of epidermal growth factor, transforming growth factor alpha, and their receptor in proliferative diabetic retinopathy. Br J Ophthalmol. 1994;78: 714-718. (Pubitemid 24275559)
19. Meyer-Schwickerath R, Pfeiffer A, Blum WF, et al. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. J Clin Invest. 1993;92:2620-2625. (Pubitemid 24006525)
20. Malvitte L, Montange T, Véjux A, et al. Measurement of inflammatory cytokines by multicytokine assay in tears of patients with glaucoma topically treated with chronic drugs. Br J Ophthalmol. 2007;91: 29-32. (Pubitemid 46094003)
21. Prunet C, Montange T, Véjux A, et al. Multiplexed flow cytometric analyses of pro-and anti-inflammatory cytokines in the culture media of oxysterol-treated human monocytic cells and in the sera of atherosclerotic patients. Cytometry A. 2006;69:359-373. (Pubitemid 44651349)
22. Imanishi J, Kamiyama K, Iguchi I, et al. Growth factors: importance in wound healing and maintenance of transparency of cornea. Prog Retin Eye Res. 2000;19:113-129.
23. Tran MT, Tellaetxe-Isusi M, Elner V, et al. Proinflammatory cytokines induce RANTES and MCP-1 synthesis in human corneal keratocytes but not in corneal epithelial cells. Beta-chemokine synthesis in corneal cells. Invest Ophthalmol Vis Sci. 1996;37:987-996.
24. Wilson SE, Mohan RR, Mohan RR, et al. The corneal wound healing response: cytokine-mediated interaction of the epithelium, stroma, and inflammatory cells. Prog Retin Eye Res. 2001;20:625-637. (Pubitemid 32695343)
25. Yoeruek E, Spitzer MS, Tatar O, et al. Safety profile of bevacizumab on cultured human corneal cells. Cornea. 2007;26:977-982. (Pubitemid 47329805)
26. Yoeruek E, Ziemssen F, Henke-Fahle S, et al. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol. 2008;86:322-328. (Pubitemid 351785106)
27. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea. 2008;27:142-147. (Pubitemid 351158729)
28. Chung JH, Fagerholm P. Treatment of rabbit corneal alkali wounds with human epidermal growth factor. Cornea. 1989;8:122-128. (Pubitemid 19167708)
29. Nezu E, Ohashi Y, Kinoshita S, et al. Recombinant human epidermal growth factor and corneal neovascularization. Jpn J Ophthalmol. 1992;36:401-406. (Pubitemid 23035193)
30. Wilson SE, Liu JJ, Mohan RR. Stromal-epithelial interactions in the cornea. Prog Retin Eye Res. 1999;18:293-309. (Pubitemid 29092609)
31. Hoppenreijs VP, Pels E, Vrensen GF, et al. Corneal endothelium and growth factors. Surv Ophthalmol. 1996;41:155-164. (Pubitemid 26322508)
32. Kuo IC. Corneal wound healing. Curr Opin Ophthalmol. 2004;15: 311-315. (Pubitemid 38962110)
33. Dana MR, Streilein JW. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci. 1996;37: 2485-2494. (Pubitemid 26391286)